Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-09-29 am EDT
81.40 CHF   -1.09%
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution
EQ
09/09Transcript : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta : Exhibits Advanced Personalized Ecosystem of digital Solutions in same day surgery setting at AAOS 2022

03/23/2022 | 09:46am EDT

- MySolutions Personalized Ecosystem, an advanced network of digital solutions intended to improve patient outcomes and healthcare efficiency. Designed for delivering value to every step of the patient journey from preoperative through postoperative care, this platform provides effective solutions for patient engagement, personalized 3D planning, precise execution, and efficient case management.

- Propel® Same Day Surgery Solutions, a full-bodied program aimed at enabling solutions for outpatient surgery, aiding the stakeholders in achieving the best outcomes at the lowest cost.
"To keep up with the changes in the medical landscape and to be able to provide patients, surgeons, and hospitals with increasingly effective and beneficial solutions, the MySolutions Personalized Ecosystem and Propel Same Day Surgery Solutions combine the company's innovations and cutting-edge technologies with tailored medical education programs and dedicated services, enabling outpatient care and same day surgery," says Francesco Siccardi, Chief Executive Officer of Medacta International. "In order to strengthen our support for the surgeon in providing personalized and even more accurate treatments for patients, we will introduce the NextARTM Augmented Reality Surgical Platform, the crown jewel of our MySolutions. This innovative solution features advanced planning tools, a revolutionary tracking system, and unique real-time guidance superimposed onto the operative field to enhance precision and enable data-driven decision-making."
With Medacta, the surgeon is never alone while discovering new technologies. These latest advancements are supported by personalized high-level educational pathways designed by the M.O.R.E. Institute, which can rely on the collaboration of an international network of expert surgeons.
Visit www.medacta.com to discover Medacta's comprehensive implant portfolio and uniquely refined surgical techniques in our Joint and Spine business lines.

Disclaimer

Medacta Group SA published this content on 23 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 March 2022 14:46:04 UTC.


© Publicnow 2022
All news about MEDACTA GROUP SA
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and..
EQ
09/09Transcript : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
09/09Swiss Orthopedic Group Medacta Lifts FY22 Outlook as H1 Revenue Grows; Profit Slows
MT
09/09Medacta : 2022 Half-Year Report
PU
09/09Medacta : 2022 Half-Year Presentation
PU
09/09Medacta Group SA reports strong revenue growth of 19.0% and adjusted EBITDA margin of 2..
EQ
09/09Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022
CI
09/08Medacta Group SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/29Transcript : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 428 M 418 M 418 M
Net income 2022 55,8 M 54,5 M 54,5 M
Net Debt 2022 137 M 134 M 134 M
P/E ratio 2022 30,1x
Yield 2022 0,73%
Capitalization 1 699 M 1 660 M 1 660 M
EV / Sales 2022 4,29x
EV / Sales 2023 3,70x
Nbr of Employees 1 421
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 85,05 €
Average target price 110,94 €
Spread / Average Target 30,4%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-42.04%1 678
ABBOTT LABORATORIES-29.86%172 880
MEDTRONIC PLC-20.16%109 775
BECTON, DICKINSON AND COMPANY-6.27%65 700
HOYA CORPORATION-19.61%34 187
DEXCOM, INC.-37.92%32 714